-
Chronic hypertension and adverse pregnancy outcomes: a cohort study.
Panaitescu AM, Syngelaki A, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:228-235. pdf -
Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Bredaki FE, Mataliotakis M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:466-71. pdf -
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
Bujold E, Roberge S, Nicolaides KH.
Prenat Diagn 2014;34:642-8. pdf -
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia.
Ferreira AF, Rezende JC, de Cassia C Oliveira R, Akolekar R, Nicolaides KH.
J Hum Hypertens 2013;27:261-4. -
Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
J Hum Hypertens 2012;26:253-8. -
Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, down's syndrome, preterm delivery and preeclampsia.
Chambers AE, Griffin C, Naif SA, Mills I, Mills WE, Syngelaki A, Nicolaides KH, Banerjee S.
Reprod Biol Endocrinol 2012;10:113. -
Maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) at 11-13 weeks in pre-eclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
Prenat Diagn 2011;31:196-201. -
Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation.
Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH.
Fetal Diagn Ther 2011;30:274-9. -
Maternal serum a-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery.
Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;30:88-93. -
Maternal serum insulin-like growth factor-I at 11-13 weeks in preeclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
Prenat Diagn 2010;30:1026-31. -
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenat Diagn 2009;29:553-9. -
First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstet Gynecol 2008;112:1082-90. -
One-stage screening for pregnancy complications by color doppler assessment of the uterine arteries at 23 weeks' gestation.
Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH.
Obstet Gynecol 2000;96:559-64.